TRIAL DETAIL
Treatment of Patients With RAD001 Who Have Progressive Sarcoma
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Treatment of Patients With RAD001 Who Have Progressive Sarcoma |
|||
NCT#: |
||||
Conditions: |
Sarcoma |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 03/01/2008 |
Age of Trial (yrs) 16.7 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
mTOR inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
CRAD001C24114, EUDRACT- Nr. 2007-005294-60 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Novartis Pharmaceuticals
+1 800-340-6843 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral
Intravenous |
|||
Trial Notes: |
The purpose of this multicenter, two-arm (sic), exact binomial single-stage, phase II trial is to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tissue sarcoma. In a separate arm, RAD001 will be tested in GIST patients that have failed or are intolerant to imatinib or sunitinib. RAD001 is an inhibitor of mTOR, an important target that is downstream of many receptor tyrosine kinases including KIT. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Berlin |
Germany |
||||
Munchen |
Germany |
||||
Dusseldorf |
Germany |
||||
Mannheim |
68135 |
Germany |
|||
Milan |
20132 |
Italy |
|||
Essen |
Germany |